Navigation Links
Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
Date:6/29/2012

THE WOODLANDS, Texas, June 29, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today the publication of results from two initial trials of LX4211 in patients with type 2 diabetes in the online edition of the journal Clinical Pharmacology & Therapeutics. The paper, containing results from both trials, is entitled, "LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients with Type 2 Diabetes in a Randomized, Placebo-controlled Trial," and will also appear in an upcoming print edition of the journal. A link to the online article can be accessed at http://www.nature.com/clpt/journal/vaop/ncurrent/full/clpt201258a.html.

"This publication represents the first peer-reviewed description of SGLT1 inhibition stimulating GLP-1 and PYY release in man," said Dr. Brian Zambrowicz, Lexicon's executive vice president and chief scientific officer. "Since LX4211 also inhibits SGLT2, the rapid and significant glycemic control and metabolic benefits observed may be attributed to effective dual inhibition of these two targets."

In the 4-week Phase 2a study described in the paper, 36 patients received once-daily oral administration of placebo or 150 mg or 300 mg of LX4211 (randomized 1:1:1) in an in-patient setting. Patients receiving LX4211 exhibited rapid and significant improvements relative to placebo in multiple measures of glycemic control, including hemoglobin A1c (HbA1c), fasting plasma glucose, and oral glucose tolerance. In addition, serum triglycerides were significantly lower at the end of the four-week treatment period, and trends of meaningful reductions in body weight and blood pressure were observed. Importantly, LX4211 treatment demonstrated a favorable safety profile and was well tolerated in the study. Also described in the paper was a subsequent clinical study conducted in a similar population of poorly-controlled patients with type 2 diabetes that showed LX4211 treatment elevated GLP-1 and PYY, two gastrointestinal peptides known to be associated with enhanced metabolic control. These elevations in GLP-1 levels after LX4211 treatment were previously suggested by data from the Phase 2a study and, hence, the repeated observation confirmed that LX4211 can act as an oral, GLP-1 secretagogue.

Lexicon recently reported top-line results from a Phase 2b double-blind study of LX4211 that extend favorable observations of the early trials to an out-patient setting in a larger population with a longer duration of therapy. The 12-week study was conducted at more than 50 centers in the United States in 299 patients with poorly-controlled diabetes despite treatment with metformin, an established diabetes therapy. Primary and secondary measures of efficacy from this study demonstrated substantial, dose-dependent, statistically-significant reductions in HbA1c, body weight and blood pressure. LX4211's dual inhibition of SGLT1 and 2 was associated with an overall favorable safety profile in the study and, notably, LX4211's inhibition of SGLT1 was associated with a favorable gastrointestinal safety profile similar to placebo.

About Lexicon
Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease. Lexicon currently has five drug programs in mid-stage development for diabetes, carcinoid syndrome, irritable bowel syndrome, rheumatoid arthritis and glaucoma, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement
This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX4211, characterizations of the results of and projected timing of clinical trials of LX4211, and the potential therapeutic and commercial potential of LX4211. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX4211 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Unless specifically indicated otherwise, results reported as trends were not statistically significant. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2011, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
2. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
3. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
4. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
5. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
6. Lexicon to Provide First Quarter 2012 Financial Results
7. Medivir Announces an Interferon-Free Phase II Combination Trial With TMC435 and daclatasvir to Commence Shortly
8. Hanger, Inc. Announces Second Quarter 2012 Earnings Release Conference Call
9. ResMed Announces Conference Call And Webcast To Discuss Fourth Quarter And Fiscal Year-End 2012 Results
10. Marshall Edwards Announces Name Change to MEI Pharma ("MEIP")
11. Access Pharmaceuticals Announces Positive Data From MuGard Phase 4 Clinical Trial In Oral Mucositis At MASCC/ISOO 2012 Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb. 23, 2017  Genesis Healthcare Services has ... announcement was made by Bill Monast , President ... and Nathan Feltman , executives with Home ... Services, LLC. This acquisition helps Hospice ... of technology enabled durable medical equipment (DME) solutions for ...
(Date:2/23/2017)... 23, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), a ... proprietary products for the urology market, will release financial ... December 31, 2016 before the market open on Thursday, ... host a conference call and webcast to discuss its ... 2017 at 11:00 a.m. Eastern Time (10:00 a.m. Central ...
(Date:2/23/2017)... Calif., Feb. 23, 2017 Nevro Corp. (NYSE: NVRO), ... solutions for the treatment of chronic pain, today reported financial ... 31, 2016. 2016 Accomplishment & Highlights: ... year 2016, an increase of 228% as reported, over the ... 2016, an increase of 612% over the prior year ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... ... Senior International Elite division on February 12th. Ms. Esparza qualified into this ... elite qualifier competition held in Las Vegas, Nevada. Frida is one of approximately ...
(Date:2/23/2017)... ... 23, 2017 , ... On February 22, 2017 the U.S. ... to withdraw previous guidance issued by the Obama Administration requiring schools to treat ... 2016 by the Obama Administration came in response to a growing number of ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare ... audience, will be participating in Rare Disease Day events, hosted by the Rare ... Rare Disease Report, a website, weekly e-newsletter and quarterly publication, will be conducting ...
(Date:2/23/2017)... ... February 23, 2017 , ... Hamlin Dental Group and Dr. Hamid ... sponsoring a raffle. Throughout the month of February, patients who visit Hamlin Dental Group ... for a dinner for two at the Cheesecake Factory. , Tickets are available ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, 2017, ... “Doping in Sport: How the Culture Might Change,” in conjunction with ... symposium will be held at Pepperdine University in Malibu, California. , Sir Philip ...
Breaking Medicine News(10 mins):